

ESCV 2021 Scientific Programme

Time	PLENARY HALL	PARALLEL HALL
15-Sep-21		
Wednesday		
07:30 - 08:30	Exhibition & Eposters Visiting Slot	
08:30 - 09:10	<p>08:30 - 08:40 Opening of the Conference <i>Mariet C.W. Feltkamp</i></p> <p>08:40 - 09:10 Opening Keynote <i>Chair: Mariet C.W. Feltkamp</i></p> <p>Main challenges of the SARS-CoV-2 pandemic, a virologist's perspective, <i>Elisabeth Puchhammer-Stöckl</i></p>	
09:10 - 10:40	<p>Session I: SARS CoV 2 Vaccines <i>Chairs: Georgios Sourvinos and Thea Kølsten Fischer</i></p> <p>9.10-9.40 The Gardner Lectureship Award: SARS-CoV-2 vaccines: Responding and adapting during a pandemic, <i>Sarah Gilbert, UK</i></p> <p>9.40-10.10 Keynote: The COVID vaccination programme - lessons and legacy, <i>Mary Ramsay</i></p> <p>10.10-10.20 Offered talk 1: SARS-CoV-2 symptomatic and asymptomatic infections after BNT162b2 vaccination in health care workers, <i>Francesca Rovida, Italy</i></p> <p>10.20-10.30 Offered talk 2: Prospective cohort study of vaccinal immunity to four SARS-CoV-2 vaccines available in Serbia as compared to naturally acquired immunity, and vaccine effectiveness: a 3-month interim report, <i>Olgica Djurkovic Djakovic, Serbia</i></p> <p>10.30-10.40 Offered talk 3: SARS-CoV-2 neutralising antibody titers against the wild type, B.1.1.7 and B.1.351 variants and the impact of some recently reported mutations, <i>Dung Nguyen, United Kingdom</i></p>	
10:40 - 11:10	Exhibition & Eposters Visiting Slot	
11:10 - 12:40	<p>Session II: Understanding SARS-CoV-2 infection <i>Chairs: Maria São José Nascimento and Paul Klapper</i></p> <p>11.10-11.40 Keynote: SARS-CoV-2, COVID-19 vaccines and immunity, <i>Florian Kramer</i></p> <p>11.40-12.10 Keynote: Long - COVID: What will be legacy from the pandemic?, <i>Chris Brightling</i></p> <p>12.10-12.20 Offered talk 4: 3D Human airway epithelial models to study SARS-CoV-2 pathogenesis, <i>Samuel Constant, Switzerland</i></p> <p>12.20-12.30 Offered talk 5: Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection, <i>Floriane Gallais, France</i></p> <p>12.30-12.40 Offered talk 6: Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans, <i>Reina S. Sikkema, Netherlands</i></p>	
12:40 - 13:40	Avacta Life Sciences Industry Symposium	QIAGEN Industry Symposium
13:40 - 15:10	<p>Session III: Next Generation Sequencing in Clinical Virology <i>Chairs: Jutte de Vries, Eric Claas and Xavier Lopez</i></p> <p>13.40-14.10 Keynote: <i>Charles Chiu</i></p> <p>14.10-14.20 Offered talk 7: NGS Diagnostic Metagenomics of The Blood Virome In Plasma From Deferred Blood Donors, <i>F. Xavier López Labador, Spain</i></p> <p>14.20-14.30 Offered talk 8: Unmasking of viral DNAs in human internal organs: distribution and within-host sequence diversities, <i>Lari Pyörriä, Finland</i></p> <p>14.30-14.40 Offered talk 9: Benchmark of thirteen bioinformatic pipelines for metagenomic virus diagnostics using datasets from clinical samples, <i>Jutte J.C. De Vries, Netherlands</i></p> <p>14.40-15.10 ENNGS Discussion on METASHARE and METASURVEILLANCE projects</p>	
15:10 - 16:00	Exhibition & Eposters Visiting Slot	
16:00 - 18:00	<p>Session IV: Offered papers in Clinical Virology <i>Chairs: Fausto Baldanti and Mariet Feltkamp</i></p> <p>16.00-16.30 The BioMérieux Award Lecture: <i>Catherine Moore, UK</i></p> <p>16.30-17.00 The Abbott Award Lecture: Cytomegalovirus and mortality in allogeneic stem cell transplantation, <i>Estela Gimenez Quiles, Spain</i></p> <p>17.00-17.15 Offered talk 10: Tick-borne encephalitis vaccination failures: a case-control study and analysis of vaccination field effectiveness in Austria from 2000 to 2018, <i>Isabel Santonja, Austria</i></p> <p>17.15-17.30 Offered talk 11: Rift Valley Fever outbreak in Mayotte; what consequences on pregnancy?, <i>Jacques Fourgeaud, France</i></p> <p>17.30-17.45 Offered talk 12: Late onset intra-uterine growth restriction: role of HHV-6 infection, <i>Silvia Beltrami, Italy</i></p> <p>17.45-18.00 Offered talk 13: Emerging norovirus infections by recombinant viral strains, <i>Noemi Navarro Lleo, Spain</i></p>	
18:00 - 19:30	Networking Time / Online Welcome Reception	

Time (BST, GMT+1)		16-Sep-21 Thursday	
Time	PLENARY HALL	PARALLEL HALL	
08:00 - 09:00	Roche Diagnostics Industry Symposium		
09:00 - 10:30	<p>Session V: The Other Respiratory Viruses Chairs: <i>Catherine Moore and Kim Benschop</i></p> <p>9.00-9.30 Keynote: RSV, Peter Openshaw</p> <p>9.30-10.00 Keynote: Antigen design of a universal influenza H5 vaccine, Ron Fouchier</p> <p>10.00-10.10 Offered talk 14: Prospective observational study to identify nosocomial acquisition of influenza and associated morbidity and mortality, Luke B Snell, UK</p> <p>10.10-10.20 Offered talk 15: Evaluation of subgenomic mRNA tests for HCoV OC43 and NL63 in respiratory tract samples from children, Inger Heimdal, Norway</p> <p>10.20-10.30 Offered talk 16: Characteristic of the delayed RSV 20/21 Respiratory Syncytial Virus Epidemic, Lyon, France, Jean Sebastien Casalegno, France</p>		
10:30 - 11:30	Exhibition & Eposters Visiting Slot		
11:30 - 13:00	<p>Session VI: Advances in Clinical Virology Chairs: <i>Javier Buesa and Heli J. Harvala</i></p> <p>11.30-12.00 The Heine-Medin Award Lecture: Zebrafish as an innovative model system of virus replication to understand gut virus infections (and beyond), Joana Rocha-Pereira, Belgium</p> <p>12.00-12.15 Offered talk 17: Improved diagnosis of viral encephalitis in adult and pediatric hematological patients using viral metagenomics, Ellen C. Carbo, Netherlands</p> <p>12.15-12.30 Offered talk 18: Neutralising Antibodies against Enterovirus and Parechovirus in IVIG as a tool for Sero-Surveillance, Karen Couderé, Belgium</p> <p>12.30-12.45 Offered talk 19: Torque teno virus load predicts allograft rejection but not viral infection after kidney transplantation, Aline L Van Rijn, Netherlands</p> <p>12.45-13.00 Offered talk 20: Post-exposure prophylaxis of respiratory diseases by inhalation of specific immunoglobulins in a porcine ex vivo lung model, Evgenii Rubalskii, Germany</p>		
13:00 - 14:00	bioMérieux Industry Symposium	QIAGEN Industry Symposium	
14:00 - 15:30	<p>Session VII: Update to HIV Chairs: <i>Pamela Vallely and Mat Donati</i></p> <p>14.00-14.30 Keynote: Progress Towards a Cure for HIV, Steven Deeks</p> <p>14.30-14.40 Offered talk 21: Background: In clinical practice, not all patients who received ART achieve the desired concordant response. Thus, this study is designed to describe the prevalence and factors associated with immunological and virological discordant response to ART, Gizachew Ayele Manaye, Ethiopia</p> <p>14.40-14.50 Offered talk 22: The clock is ticking for HIV - Pharmacological activation of the circadian system inhibits HIV-1 replication, Helene Borrmann, UK</p> <p>14.50-15.00 Offered talk 23: Number, type and cost of microbiological assays during HIV Pre-Exposure Prophylaxis: the experience of a French hospital, Quentin Lepiller, France</p>		
14:00 - 14:50	Exhibition & Eposters Visiting Slot		
16:30 - 18:00	<p>Session VIII: Clinical Cases Chairs: <i>William Irving and Kate Templeton</i></p> <p>16.30-16.45 Offered case 24: Human bocavirus 1 respiratory tract re-activations or re infections in two adults, contributing to neurologic deficits and death, Rajita Rayamajhi Thapa, Finland</p> <p>16.45-17.00 Offered case 25: Severe Meningoencephalitis Caused by Late Reactivation of Herpes B Virus after a Marmoset Bite, Sander Van Boheemen, Netherlands</p> <p>17.00-17.15 Offered case 26: Intra host variants in hospitalized immunocompetent and immunocompromised patients infected with SARS-CoV-2, Ellen C. Carbo, Netherlands</p> <p>17.15-17.30 Offered case 27: A case of fulminant transfusion-transmitted hepatitis E virus infection in England, 2019, Heli J. Harvala, United Kingdom</p> <p>17.30-17.45 Offered case 28: Investigating a prolonged untypeable enterovirus infection in a severely ill patient using long-read sequencing, Hayley Cassidy, Netherlands</p>		
18:00 - 19:00	General Assembly (Only for ESCV members)		

Time (BST, GMT+1)		17-Sep-21 Friday	
Time	PLENARY HALL	PARALLEL HALL	
08:00 - 09:00	Siemens Healthcare Industry Symposium	Abbott Industry Symposium	
09:00 - 10:30	<p>Session IX: UKCVN (UK Clinical Virology Network) Session I Chairs: <i>Stephen Winchester and Mark Zuckerman</i></p> <p>09.00 – 9.30 Keynote: Screening for HTLV, Graham Taylor, UK</p> <p>09.30 – 9.45 Oral presentation CVN 1: Kidney transplants from HCV positive donors into HCV negative recipients, Sarah Browne, UK</p> <p>09.45 – 10.00 Oral presentation CVN 2: High level compliance to opt out HIV testing in the Emergency Department (ED) of a large teaching hospital using the biochemistry sample as the sample type for HIV screening, Rebecca Marchant, UK</p> <p>10.00 – 10.15 Oral presentation CVN 3: Detection of DNA viruses in CSF: Development of a metagenomic next generation sequencing assay as a diagnostic tool for unknown aetiology cases, Carmen Manso, UK</p> <p>10.15 – 10.30 Oral presentation CVN 4: The use of Post-exposure prophylaxis for VZV in pregnant women in Lothian January 2016-July 2018, Fiona J Hamilton, UK</p>		
10:30 - 10:50	Break		
10:50 - 12:20	<p>Session X: UKCVN (UK Clinical Virology Network) Session II Chairs: <i>Stephen Winchester and Mark Zuckerman</i></p> <p>10.50 – 11.20 Keynote: Dengue virus vaccine and diagnostic challenges, Peter Laing, UK</p> <p>11.20 – 11.50 Keynote: What's new in congenital and post-natal CMV infection, Seilesh Kadambari, UK</p> <p>11.50 – 12.05 Oral presentation CVN 5: Persistent Influenza A(H1N1)pdm09 shedding in an immunocompromised patient, Ben Canning, UK</p> <p>12.05 – 12.20 Oral presentation CVN 6: Amino acid variations in HBsAg Influence Hepatitis B Virus entry into HuH7 cells, Chidinma Raymond, UK</p>		
12:20 - 13:00	<p>E-Poster Discussion Session I</p> <p>Detection of SARS-CoV-2 by conventional methods, Carla Berengua, Spain</p> <p>SARS-CoV-2 variability in North-East of France - modulation in spike gene according to time and tissue distribution, Evelyne Schvoeuer, France</p> <p>Humoral and cell-mediated response against SARS-CoV-2 elicited by mRNA vaccine BNT162b2, Irene Cassaniti, Italy</p> <p>Virological follow-up protocols applied in the European countries: a survey on prolonged SARS-CoV-2 RNA detection (March-June 2020), Laura Bubba, Italy</p> <p>Repurposing ACE2 inhibitor (DX-600) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, Muhammed Miran Öncel, Turkey</p> <p>Heterogeneous virological and serological characteristics of severely ill COVID-19 patients in the United Kingdom: considerations for therapeutic clinical trial design and subgroup analysis, Jeremy Ratcliff, United Kingdom</p> <p>Monitoring the circulation of SARS-CoV-2 variants: correlation of mutations detection by specific RT-PCR and whole genome sequencing by NGS, Véronique Jacomo, France</p> <p>SARS-CoV-2 Cycle threshold (Ct) values predict future COVID-19 cases, Matthew C Phillips, United States</p>	<p>Exploring the diversity of orphan viruses in human blood, Maria Cebriá Mendoza, Spain</p> <p>Evaluation of a metagenomics platform for the detection and quantification of transplant-related viruses, Nadine Lübke, Germany</p> <p>Current practices of management of maternal and congenital Cytomegalovirus infection during pregnancy after a maternal primary infection occurring in first trimester of pregnancy: systematic review, Claire Perillaud Dubois, France</p> <p>Humoral response to SARS-CoV-2 vaccine in a cohort of health care workers: Real world data from a single University Hospital Center in Portugal, Joana Oliveira Silva, Portugal</p> <p>Rapid detection of SNPs in human innate genes IFITM3 and ATG16L1 to identify individuals susceptible to severe influenza virus (IAV) infection, Luke Dylan Griffith, United Kingdom</p> <p>The Epidemiology and Etiologies of Respiratory Tract Infection During The Early Phase of Coronavirus Disease 2019 Outbreak in the Northern Taiwan, Andrew Po Liang Chen, Taiwan</p> <p>In the setting of HDV co-infection, HBeAg strongly correlates with higher HDV replicative activity and enhanced cytolytic activity, Romina Salpini, Italy</p> <p>Evaluation of HBeAg level in the different HBV infection phases and its role in predicting therapeutic outcome in the setting of HBV reactivation, Lorenzo Piermatteo, Italy</p>	
13:00 - 14:00	QIAGEN Industry Symposium	Diasorin Molecular Industry Symposium	
14:00 - 15:00	<p>Session XI: Update to hepatitis Chairs: <i>Marcus Panning and William Irving</i></p> <p>14.00-14.30 Keynote: Update on hepatitis B therapy, Man-Fung Yuen</p> <p>14.30-14.40 Offered talk 29: In Vitro and In Vivo Antiviral Properties of GST-HG141, a Novel Hepatitis B Virus Capsid Assembly Modulator in Clinical Development, Vadim Bichko, United States</p> <p>14.40-14.50 Offered talk 30: Hepatitis B infections among blood donors in England between 2009 and 2018: focus on occult HBV, Heli J. Harvala, United Kingdom</p> <p>14.50-15.00 Offered talk 31: A Decade of Phylogenetic and Epidemiological Surveillance of HEV in Germany, 2010-2019, Mathias Schemmerer, Germany</p>		
15:00 - 15:30	Break		
15:30 - 18:10	<p>15:30 - 18:00 Session XII: Pandemic Preparedness Clinical Virology Discussion Chair: <i>Vincent Racaniello</i></p> <p>18:00 - 18:10 Closing of the Conference</p>		